Protagonist Therapeutics (NASDAQ:PTGX) Reaches New 1-Year High on Analyst Upgrade
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Truist Financial raised their price target on the stock from $60.00 to $76.00. Truist Financial currently has a buy rating on the stock. Protagonist Therapeutics traded as high as $58.57 and last traded at $58.04, with a […]
Protagonist Therapeutics, Inc. (NASDAQ:PTGX – Get Free Report)’s stock price reached a new 52-week high on Tuesday after Truist Financial raised their price target on the stock from $60.00 to $76.00. Truist Financial currently has a buy rating on the stock. Protagonist Therapeutics traded as high as $58.57 and last traded at $58.04, with a […]
